MannKind Corporation Stock News

MannKind Corporation (NASDAQ:MNKD ) Q2 2025 Earnings Call August 6, 2025 9:00 AM ET Company Participants Christopher B. Prentiss - Chief Financial Officer Michael E.

Today, we take another look at MannKind Corporation, which specializes in inhaled therapeutics for endocrine and orphan lung diseases, with a market cap of $1.15 billion. The company just reported second-quarter results and continues to enjoy universal support from the analyst firm community. MannKind saw decent growth from its two core products on the market in Q2 and just signed a new non-dil...

MannKind (MNKD -9.52%), a biopharmaceutical firm known for its inhaled insulin and pulmonary therapeutics, released its second quarter 2025 earnings on August 6, 2025. The most significant news from this release was a 6% increase in total revenue to $76.53 million (GAAP), primarily from royalty gains and higher Afrezza inhaled insulin sales.

Strengthens MannKind's capital structure with flexible, long-term, non-dilutive funding MannKind to receive $75 million in cash at closing DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

2Q 2025 revenues of $76.5M, +6% v. 2Q 2024 YTD 2025 revenues of $154.9M, +12% v.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Session

WESTLAKE VILLAGE, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will team up with NTT INDYCAR SERIES driver Conor Daly, who is living with Type 1 diabetes (T1D) for a one-of-a-kind experience with Detroit area youth and families during the week of the Chevrolet Detroit Grand Prix in downtown Detroit.